达雷妥尤单抗诱导的急性闭角型青光眼:骨髓移植作为一个可能的危险因素以及阿托品化作为一种潜在的解决办法。
Daratumumab-induced acute angle closure glaucoma: bone marrow transplantation as a possible risk factor and atropinization as a potential solution.
作者信息
Yuksel Elgin Cansu, Atseven Ahmet Fırat, Mammadzada Ofeliya, Ocakoğlu Özcan
机构信息
Istanbul University-Cerrahpasa, Istanbul, Türkiye.
出版信息
BMC Ophthalmol. 2025 Jul 1;25(1):382. doi: 10.1186/s12886-025-04214-5.
This case report describes a 29-year-old female with recurrent T-cell Acute Lymphoblastic Leukemia who developed acute angle closure glaucoma (AACG) following daratumumab infusion. The patient, with a history of bone marrow transplantation and head-neck radiotherapy, experienced sudden eye pain and blurred vision minutes after treatment initiation. Ophthalmological examination revealed bilateral closed angles and elevated intraocular pressure. Ultrasound biomicroscopy showed ciliary malrotation and effusion, suggesting choroidal effusion secondary to daratumumab. The condition was successfully managed with topical medications and subsequent infusions were administered with atropine premedication, preventing recurrence. This case highlights bone marrow transplantation as a potential risk factor for daratumumab-induced AACG and demonstrates the effectiveness of atropinization in managing this complication.
本病例报告描述了一名29岁复发性T细胞急性淋巴细胞白血病女性患者,在输注达雷妥尤单抗后发生急性闭角型青光眼(AACG)。该患者有骨髓移植和头颈放疗史,在开始治疗数分钟后出现突发眼痛和视力模糊。眼科检查发现双侧房角关闭和眼压升高。超声生物显微镜检查显示睫状体旋转不良和积液,提示达雷妥尤单抗继发脉络膜积液。该病症通过局部用药成功得到控制,随后的输注给予阿托品预处理,防止复发。本病例突出了骨髓移植作为达雷妥尤单抗诱导AACG的潜在危险因素,并证明了阿托品化在处理该并发症方面的有效性。